论文部分内容阅读
目的:观察雾化吸入重组人干扰素α-2b治疗小儿毛细支气管炎的疗效,并探讨其作用机理。方法:将175例毛细支气管炎患儿随机分为两组,治疗组90例,对照组85例。对照组采用常规治疗并加用普米克令舒雾化液压缩雾化吸入;治疗组在对照组治疗的基础上加用重组人α-2b干扰素压缩雾化吸入,疗程5天,观察患儿体温、咳喘、肺部啰音消失时间、平均住院日及药物副作用。结果:治疗组在患儿体温、咳喘、肺部啰音消失时间、平均住院日等方面均明显优于对照组(P<0.01),其药物副作用两组比较无明显差异。结论:雾化吸入重组人干扰素α-2b治疗小儿毛细支气管炎的疗效显著,副作用少,值得临床推广应用。
OBJECTIVE: To observe the therapeutic effect of inhaled recombinant human interferon α-2b on children’s bronchiolitis and to explore its mechanism. Methods: 175 cases of bronchiolitis were randomly divided into two groups, the treatment group 90 cases, control group 85 cases. The control group was treated with routine treatment and pulmonic fluid inhalation by inhalation. The treatment group was treated with inhaled recombinant human α-2b interferon for 5 days on the basis of the control group, and the treatment group was observed for 5 days Body temperature, cough and wheezing, pulmonary rales disappear time, average length of stay and drug side effects. Results: The treatment group was significantly better than the control group (P <0.01) in terms of body temperature, cough and wheezing, disappearance of pulmonary rales and average length of stay. There was no significant difference in side effects between the two groups. Conclusion: Inhaled recombinant human interferon α-2b treatment of children with bronchiolitis significant effect, less side effects, it is worthy of clinical application.